S&P Futures
4,305.50 -2.25 (-0.05%) Dow Futures
34,111.00 -7.00 (-0.02%) Nasdaq Futures
13,644.75 -13.50 (-0.10%) Russell 2000 Futures
2,023.10 -0.20 (-0.01%) Crude Oil
86.57 +0.04 (+0.05%) Gold
1,789.40 -0.30 (-0.02%)
Regencell Bioscience Holdings Limited (RGC)
Chart Events
Performance Outlook
| Previous Close | 31.68 |
| Open | 31.43 |
| Bid | 28.82 x 900 |
| Ask | 48.08 x 2900 |
| Day's Range | 29.80 - 31.43 |
| 52 Week Range | 6.00 - 59.00 |
| Volume | |
| Avg. Volume | 10,980 |
| Market Cap | 399.496M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.41 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RGC
Related Research
- Regencell Bioscience Holdings LCNK: Raising target price to $12.00CINEMARK HOLDINGS INC has an Investment Rating of SELL; a target price of $12.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat2 months agoArgus Research
- Zacks Small Cap Research
RGC: CEO Figuratively Putting His Money Where His Mouth Is
By Beth Senko, CFA NASDAQ:RGC Investors have faced challenging and volatile markets so far in 2022 as they sort through issues of inflation, supply chain disruption, continued covid issues, rising interest rates, and the disruption of the war in Ukraine. The S&P 500 has come close to bear market levels, down 19% in mid-June. Times of turbulence affect all stocks, large and small. It can be
- Zacks Small Cap Research
RGC: Second investigational study of RGC-COV19™ replicates results of earlier trial in eliminating COVID-19 symptoms.
By Beth Senko, CFA NASDAQ:RGC Founded in 2014, Hong Kong-based Regencell Bioscience (NASDAQ:RGC) is an early clinical stage bioscience company using Traditional Chinese Medicine (TCM) approach to develop standardized TCM formulas to holistically treat autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children, and infectious diseases such as the coronavirus
- Business Wire
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period
HONG KONG, May 18, 2022--Regencell Bioscience Holdings Limited (NASDAQ: RGC):
